Antagonising angiogenesis in rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic systemic disease characterised by an inflammatory erosive synovitis. Early changes in the synovium are marked by neovascularisation, inflammatory cell infiltration, and associated synoviocyte hyperplasia, which produce a pannus of inflammatory vascular tissue. This pannus covers and erodes articular cartilage, eventually leading to joint destruction. Angiogenesis is a complex, highly regulated physiological process, which in normal adults is restricted to the female reproductive cycle and wound healing. A coordinated sequence of endothelial cell division, selective degradation of vascular basement membranes and surrounding extracellular matrix (ECM) with migration of endothelial cells1 results in new capillary growth from existing vessels. Pathological angiogenesis is now recognised as a fundamental component of pannus development in RA,2 with evidence of both focal endothelial proliferation and apoptosis in the synovium.3 The importance of angiogenesis in providing the vascular network to sustain synovial and immune cell proliferation is confirmed by pharmacological inhibition of angiogenesis, resulting in suppression of arthritis in experimental models.4-7 More recently, specific inhibition of vascular endothelial growth factor (VEGF) by soluble receptor, sflt-1,8 and by anti-VEGF antibody9 has been shown to attenuate collagen induced arthritis in mice, supporting the major role of VEGF in promoting angiogenesis. The initiation of angiogenesis is associated with expression of a number of angiogenic growth factors of which basic fibroblast growth factor-2 (FGF-2) and VEGF are the most potent.10 In RA, high levels of VEGF,11 FGF-1,12FGF-2,13 transforming growth factor β1(TGFβ1),14 and hepatocyte growth factor15 are present in synovial fluid (SF) or synovial membrane, secreted by synoviocytes or infiltrating leucocytes. The presence of these angiogenic factors confirms earlier studies showing that SF induces capillary-like structures in endothelial cell cultures.16 We have investigated the control of VEGF production …

[1]  R. Strieter,et al.  Cytokines in rheumatoid arthritis. , 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[2]  P Merry,et al.  A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. , 2010, Arthritis and rheumatism.

[3]  N. Ferrara,et al.  Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.

[4]  R. Baker,et al.  Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis , 1999, Nature Medicine.

[5]  G. Haines,et al.  Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. , 1996, Arthritis and rheumatism.

[6]  D. Kamp,et al.  Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. , 1988, Biochemical and biophysical research communications.

[7]  E. Edelman,et al.  Cellular Response to Transforming Growth Factor-β1 and Basic Fibroblast Growth Factor Depends on Release Kinetics and Extracellular Matrix Interactions* , 1996, The Journal of Biological Chemistry.

[8]  J. Turnbull,et al.  Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. , 1992, The Journal of biological chemistry.

[9]  T. Dexter,et al.  Cell adhesion in the stromal regulation of haemopoiesis. , 1992, Bailliere's clinical haematology.

[10]  M. Goldberg,et al.  Sequencing of the human vascular endothelial growth factor (VEGF) 3' untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. , 1997, Biochimica et biophysica acta.

[11]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[12]  O. Pappo,et al.  Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis , 1999, Nature Medicine.

[13]  K. Fujii,et al.  Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis. , 1998, Arthritis and rheumatism.

[14]  T. Maciag,et al.  The heparin-binding (fibroblast) growth factor family of proteins. , 1989, Annual review of biochemistry.

[15]  K. Alitalo,et al.  Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. , 1994, The Journal of biological chemistry.

[16]  R. Turner,et al.  Rheumatoid arthritis and osteoarthritis synovial fluid effects on primary human endothelial cell cultures. , 1985, The Journal of rheumatology.

[17]  D. Moscatelli.  Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells , 1988, The Journal of cell biology.

[18]  S. Soker,et al.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. , 1992, The Journal of biological chemistry.

[19]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.

[20]  D. Rees,et al.  Diversity does make a difference: fibroblast growth factor-heparin interactions. , 1998, Current opinion in structural biology.

[21]  E. Brahn,et al.  Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. , 1994, Cellular immunology.

[22]  S. Jimenez,et al.  Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[23]  R. Maciewicz,et al.  Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis , 2000, Laboratory Investigation.

[24]  J. Rosenbaum,et al.  Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[25]  J. Case,et al.  Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints , 1990, The Journal of cell biology.

[26]  R. F. Sewell,et al.  Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate. , 1989, The Biochemical journal.

[27]  J. Jackson,et al.  Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. , 1997, The Journal of rheumatology.

[28]  S. Antonarakis,et al.  Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Goodman,et al.  Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist , 1999 .

[30]  A. Koch.  Review: angiogenesis: implications for rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[31]  G. Firestein,et al.  Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. , 1999, The Journal of clinical investigation.

[32]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[33]  J. Levick,et al.  Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure. , 1990, The Journal of rheumatology.

[34]  E. Brahn,et al.  Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). , 1995, Cellular immunology.

[35]  Bottomley,et al.  Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up‐regulation by tumour necrosis factor‐alpha (TNF‐α) in synovial fluid , 1999, Clinical and experimental immunology.

[36]  C. Patterson,et al.  Induction of Vascular Endothelial Growth Factor Gene Expression by Interleukin-1 in Rat Aortic Smooth Muscle Cells (*) , 1995, The Journal of Biological Chemistry.

[37]  P. Bohlen,et al.  Cloning and functional expression of a human heparanase gene. , 1999, Biochemical and biophysical research communications.

[38]  B. Berse,et al.  Hypoxia augments cytokine (transforming growth factor‐beta (TGF‐β) and IL‐1)‐induced vascular endothelial growth factor secretion by human synovial fibroblasts , 1999, Clinical and experimental immunology.

[39]  E. Brahn,et al.  Angiogenesis inhibition suppresses collagen arthritis , 1992, The Journal of experimental medicine.

[40]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[41]  A. Koch,et al.  Angiogenesis: Implications for rheumatoid arthritis , 1998 .

[42]  J. Erusalimsky,et al.  Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. , 1995, Circulation.

[43]  R. Weinberg,et al.  A molecular basis of cancer. , 1983, Scientific American.

[44]  H. Shimano,et al.  Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. , 2001, Biochemical and biophysical research communications.

[45]  D. A. Walsh,et al.  Focally regulated endothelial proliferation and cell death in human synovium. , 1998, The American journal of pathology.

[46]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.